A Phase 3 interventional study of Aripiprazole and Placebo in Bipolar Disorder Mania, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 73 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-12-02.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing aripiprazole in Bipolar Disorder — none open to participants now, none under way, none of them phase 3. Aripiprazole · Bipolar Disorder.
Among the 39 studies testing aripiprazole in Bipolar Disorder, this one is the 5th largest by enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2008, is one of 16 in phase 3, and was the 32nd registered.
1,686 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.
Browse Bipolar Disorder studies →None of the 39 studies testing aripiprazole in Bipolar Disorder is open now. The open studies under Bipolar Disorder, anywhere →
Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 4 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 493 is above the median of 64 across 1,281 interventional studies indexed under Bipolar Disorder.
Median enrollment 48 across the 37 interventional studies. Of the 37 that completed or were terminated, 15 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 39 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
21 studies in Bipolar Disorder by Otsuka Holdings Co., Ltd.: 1 open now, 1 under way, 1 of them phase 3. Of 19 finished, 5 (26%) have results posted.
Among the 21 studies in Bipolar Disorder by Otsuka Holdings Co., Ltd., this one is the 5th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2008, is one of 11 in phase 3, and was the 17th registered.
Otsuka Holdings Co., Ltd.’s Bipolar Disorder studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 39 studies testing aripiprazole in Bipolar Disorder, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 21 in Bipolar Disorder:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to determine whether aripiprazole provides additional clinical benefit to patients with Bipolar I disorder when combined with lithium or valproate over 12 weeks.
Key inclusion criteria:
Key exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomly received placebo (1:1 to study drug) as adjunctive therapy to current ongoing treatment with valproate or lithium for 12 weeks.
Drug: Placebo · Drug: Lithium · Drug: Valproate
Participants randomly received aripiprazole as adjunctive therapy to current ongoing treatment with valproate or lithium for 12 weeks. Aripiprazole was provided in 5-, 10-, or 15-mg oral tablets and administered at a starting dose of 5 mg per day for Week 1. For Weeks 2 through 3, the dose was titrated up to 10 mg per day, and for Weeks 4 through 6, the dose increased to 15 mg per day. Flexible doses of either 15 or 30 mg per day were administered for Weeks 7 through 12. If participants were unable to tolerate the dose of 15 mg per day of study drug, the dose was decreased to 10 mg per day for Weeks 7 through 12.
Drug: Aripiprazole · Drug: Lithium · Drug: Valproate
5-, 10-, or 15-mg oral tablets in titrated doses for 12 weeks
Also known as: Abilify, BMS-337039
Tablets, Oral, 0 mg, once daily, 12 weeks
Participant's ongoing dose
Participant's ongoing dose
Change From Baseline in Total Score on the Young Mania Rating Scale (YMRS) (LOCF Data Set)
The YMRS is a clinician-administered scale, consisting of 11 multiple choice items, and used to assess a patient's manic symptoms and clinical condition over the previous 48 hours. Total scores range from 0 to 60, with 12 or greater signifying hypomania or mania. Each item is given a severity rating ranging from 0 to 8 or 0 to 4. Items for the scale are based on the core symptoms of mania: elevated mood, increased motor activity, sexual interest, sleep, irritability, speech (rate and amount), language-though disorder, content, disruptive-aggressive behavior, appearance, and insight. Scores for each item reflect the severity of that symptom in the patient. The test is administered during a clinical interview typically lasting 15-30 minutes. LOCF=last observation carried forward.
Time frame: Baseline to Week 12
Change From Baseline in Score on Clinical Global Impression-Bipolar Version (CGI-BP) Severity of Illness (Mania) Scale (LOCF Data Set)
Adjusted mean change. The CGI-BP is a scale used to assess a clinician's impression of a patient's illness. Each patient is rated at baseline and at subsequent visits on items related to severity of depression, mania, and overall bipolar illness. The CGI-BP is a 7-point scale, with scores ranging from 1=normal/not ill to 7=very severely ill. Higher total score indicates greater severity of illness. LOCF=last observation carried forward.
Time frame: Baseline to Weeks 3, 6, 9, and 12
Change From Baseline in Score on Clinical Global Impression-Bipolar Version (CGI-BP) Severity of Illness (Depression) Scale (LOCF Data Set)
Adjusted mean change. The CGI-BP is a scale used to assess a clinician's impression of a patient's illness. Each patient is rated at baseline and at subsequent visits on items related to severity of depression, mania, and overall bipolar illness. The CGI-BP is a 7-point scale, with scores ranging from 1=normal/not ill to 7=very severely ill. Higher total score indicates greater severity of illness. LOCF=last observation carried forward.
Time frame: Baseline to Weeks 3, 6, 9, and 12
Change From Baseline in Score on Clinical Global Impression-Bipolar Version (CGI-BP) Severity of Illness (Overall) Scale at Week 12 (LOCF Data Set)
Adjusted mean change. The CGI-BP is scale used to assess a clinician's impression of a patient's illness. Each patient is rated at baseline and at subsequent visits on items related to severity of depression, mania, and overall bipolar illness. The CGI-BP is a 7-point scale, with scores ranging from 1=normal/not ill to 7=very severely ill. Higher total score indicates greater severity of illness. LOCF=last observation carried forward.
Time frame: Baseline to Week 12
Change From Baseline in Total and Subscale Scores on the Functional Assessment Short Test (FAST)(LOCF Data Set)
The FAST is an interview-administered instrument used to assess the main functioning problems that patients with bipolar disorder experience. Participants are rated at Baseline, Week 3, Week 6, Week 9, and Week 12/End of Study Visit. The FAST consists of 24 items that assess impairment or disability in 6 specific areas of functioning, categorized as the subscales: autonomy, occupational functioning, cognitive functioning, financial issues, interpersonal (IP) relationships, and leisure time. All items are rated using a 4-point scale, 0=no difficulty, 1=mild difficulty, 2=moderate difficulty, and 3=severe difficulty. The global score is the sum of the scores of all items and ranges from 0 (0\*24)to 96 (4\*24). The higher the global score, the higher the level of impairment. function=functioning. LOCF=last observation carried forward.
Time frame: Baseline to Weeks 3, 6, 9, and 12
Percentage of Participants Showing A Response From Baseline on the Young Mania Rating Scale (YMRS)(OC Data Set)
Response on the YMRS is defined as a 50% or greater improvement from baseline in YMRS total score. The YMRS is clinician-administered and consists of 11 multiple choice items. It is used to assess a patient's manic symptoms and clinical condition over the previous 48 hours. Total scores range from 0 to 60, with 12 or greater signifying hypomania or mania. Each item is given a severity rating ranging from 0 to 8 or 0 to 4. Items for the scale are based on the core symptoms of mania: elevated mood, increased motor activity, sexual interest, sleep, irritability, speech (rate and amount), language-thought disorder, content, disruptive-aggressive behavior, appearance, and insight. Scores for each item reflect the severity of that symptom in the patient. The test is administered during a clinical interview typically lasting 15-30 minutes. OC=observed cases.
Time frame: Baseline to Weeks 3, 6, 9, and 12
Percentage of Participants Showing Remission in the Young Mania Rating Scale (YMRS) Score From Baseline (LOCF Data Set)
Remission is defined as a YMRS total score of 12 or less. The YMRS is clinician-administered and consists of 11 multiple choice items. It is used to assess a patient's manic symptoms and clinical condition over the previous 48 hours. Total scores range from 0 to 60, with 12 or greater signifying hypomania or mania. Each item is given a severity rating ranging from 0 to 8 or 0 to 4. Items for the scale are based on the core symptoms of mania: elevated mood, increased motor activity, sexual interest, sleep, irritability, speech (rate and amount), language-thought disorder, disruptive-aggressive behavior, appearance, and insight. Scores for each item reflect the severity of that symptom in the patient. The test is administered during a clinical interview typically lasting 15-30 minutes. LOCF=last observation carried forward.
Time frame: Baseline to Weeks 3,6, 9, and 12
Change From Baseline in Total Score on the Longitudinal Interval Follow-up Evaluation-Rating Impaired Functioning Tool (LIFE-RIFT)(OC Data Set and Week 12 LOCF Data Set)
Adjusted mean change. The LIFE-RIFT total score ranges from 4 to 20 and is the sum of scores of 4 items: work, interpersonal relations, satisfaction, and recreation. A negative change score signifies improvement. OC=observed cases; LOCF=last observation carried forward.
Time frame: Baseline to Weeks 6 and 12
Participant Scores on Patient Global Impression Improvement (PGI-I) Scale (OC Data Set)
Adjusted Mean Scores. The PGI-I is a self-administered 7-point scale, with scores ranging from 1 (very much improved) to 7 (very much worse), that assesses the improvement or worsening of a patient's illness relative to baseline at the beginning of the intervention. Scores: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; or 7=very much worse. OC=observed cases.
Time frame: Baseline to Weeks 3, 6, 9, and 12
Change From Baseline in Participant Weight (OC Data Set and Week 12 LOCF Data Set)
Adjusted mean change.OC=observed cases; LOCF=last observation carried forward.
Time frame: Baseline to Weeks 3, 6, 9, and 12
Percentage of Participants With Relevant Weight Gain or Weight Loss From Baseline at Week 12 (LOCF Data Set)
Relevant weight gain=7% or greater increase in weight; relevant weight loss=7% or greater decrease in weight. LOCF=last observation carried forward.
Time frame: Baseline to Weeks 3, 6, 9, and12
Change From Baseline to Week 12 in Body Mass Index (BMI) (LOCF Data Set)
BMI=Weight in kilograms /(Height in meters\^2). LOCF=last observation carried forward.
Time frame: Baseline to Week 12
| Milestone | Placebo + Valproate or Lithium | Aripiprazole + Valproate or Lithium |
|---|---|---|
| Started | 189 | 181 |
| Completed | 131 | 122 |
| Not completed | 58 | 59 |
| Withdrew: Lack of efficacy | 11 | 10 |
| Withdrew: Adverse event | 25 | 23 |
| Withdrew: Withdrawal by subject | 11 | 14 |
| Withdrew: Lost to follow-up | 3 | 5 |
| Withdrew: Poor compliance/noncompliance | 3 | 5 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: No longer meets study criteria | 0 | 1 |
| Withdrew: Other reasons | 4 | 1 |
The YMRS is a clinician-administered scale, consisting of 11 multiple choice items, and used to assess a patient's manic symptoms and clinical condition over the previous 48 hours. Total scores range from 0 to 60, with 12 or greater signifying hypomania or mania. Each item is given a severity rating ranging from 0 to 8 or 0 to 4. Items for the scale are based on the core symptoms of mania: elevated mood, increased motor activity, sexual interest, sleep, irritability, speech (rate and amount), language-though disorder, content, disruptive-aggressive behavior, appearance, and insight. Scores for each item reflect the severity of that symptom in the patient. The test is administered during a clinical interview typically lasting 15-30 minutes. LOCF=last observation carried forward.
| Units on a scale | Placebo + Valproate or Lithium | Aripiprazole + Valproate or Lithium |
|---|---|---|
| Change From Baseline in Total Score on the Young Mania Rating Scale (YMRS) (LOCF Data Set) | -11.54 ± 0.78 | -13.57 ± 0.78 |
Adjusted mean change. The CGI-BP is a scale used to assess a clinician's impression of a patient's illness. Each patient is rated at baseline and at subsequent visits on items related to severity of depression, mania, and overall bipolar illness. The CGI-BP is a 7-point scale, with scores ranging from 1=normal/not ill to 7=very severely ill. Higher total score indicates greater severity of illness. LOCF=last observation carried forward.
| Units on a scale | Placebo + Valproate or Lithium | Aripiprazole + Valproate or Lithium |
|---|---|---|
| Week 3 (n=183, 174) | -0.97 ± 0.08 | -0.93 ± 0.08 |
| Week 6 (n=186, 176) | -1.35 ± 0.09 | -1.46 ± 0.10 |
| Week 9 (n=186, 176) | -1.55 ± 0.10 | -1.83 ± 0.11 |
| Week 12 (n=186, 176) | -1.78 ± 0.11 | -2.07 ± 0.11 |
Adjusted mean change. The CGI-BP is a scale used to assess a clinician's impression of a patient's illness. Each patient is rated at baseline and at subsequent visits on items related to severity of depression, mania, and overall bipolar illness. The CGI-BP is a 7-point scale, with scores ranging from 1=normal/not ill to 7=very severely ill. Higher total score indicates greater severity of illness. LOCF=last observation carried forward.
| Units on a scale | Placebo + Valproate or Lithium | Aripiprazole + Valproate or Lithium |
|---|---|---|
| Week 3 (n=183, 174) | -0.01 ± 0.05 | -0.09 ± 0.05 |
| Week 6 (n=186, 176) | -0.02 ± 0.06 | -0.01 ± 0.06 |
| Week 9 (n=186, 176) | -0.04 ± 0.07 | 0.11 ± 0.07 |
| Week 12 (n=186, 176) | -0.03 ± 0.08 | 0.14 ± 0.08 |
Adjusted mean change. The CGI-BP is scale used to assess a clinician's impression of a patient's illness. Each patient is rated at baseline and at subsequent visits on items related to severity of depression, mania, and overall bipolar illness. The CGI-BP is a 7-point scale, with scores ranging from 1=normal/not ill to 7=very severely ill. Higher total score indicates greater severity of illness. LOCF=last observation carried forward.
| Units on a scale | Placebo + Valproate or Lithium | Aripiprazole + Valproate or Lithium |
|---|---|---|
| Change From Baseline in Score on Clinical Global Impression-Bipolar Version (CGI-BP) Severity of Illness (Overall) Scale at Week 12 (LOCF Data Set) | -1.51 ± 0.11 | -1.59 ± 0.11 |
The FAST is an interview-administered instrument used to assess the main functioning problems that patients with bipolar disorder experience. Participants are rated at Baseline, Week 3, Week 6, Week 9, and Week 12/End of Study Visit. The FAST consists of 24 items that assess impairment or disability in 6 specific areas of functioning, categorized as the subscales: autonomy, occupational functioning, cognitive functioning, financial issues, interpersonal (IP) relationships, and leisure time. All items are rated using a 4-point scale, 0=no difficulty, 1=mild difficulty, 2=moderate difficulty, and 3=severe difficulty. The global score is the sum of the scores of all items and ranges from 0 (0\*24)to 96 (4\*24). The higher the global score, the higher the level of impairment. function=functioning. LOCF=last observation carried forward.
| Units on a scale | Placebo + Valproate or Lithium | Aripiprazole + Valproate or Lithium |
|---|---|---|
| Total score: Week 3 (n=179, 169) | -5.68 ± 0.86 | -5.00 ± 0.87 |
| Total score: Week 6 (n=182, 171) | -8.59 ± 0.98 | -6.93 ± 0.99 |
| Total score: Week 9 (n=182, 171) | -9.18 ± 1.06 | -7.71 ± 1.07 |
| Total score: Week 12 (n=182, 171) | -10.39 ± 1.09 | -8.51 ± 1.10 |
| Autonomy score: Week 3 (n=179, 169) | -0.93 ± 0.18 | -0.93 ± 0.18 |
| Autonomy score: Week 6 (n=182, 171) | -1.44 ± 0.19 | -1.11 ± 0.19 |
| Autonomy score: Week 9 (n=182, 171) | -1.56 ± 0.21 | -1.20 ± 0.21 |
| Autonomy score: Week 12 (n=182, 171) | -1.84 ± 0.21 | -1.45 ± 0.21 |
| Occupational function score: Week 3 (n=179, 169) | -0.65 ± 0.25 | -1.00 ± 0.25 |
| Occupational function score: Week 6 (n=182, 171) | -1.23 ± 0.29 | -1.40 ± 0.29 |
| Occupational function score: Week 9 (n=182, 171) | -1.20 ± 0.30 | -1.22 ± 0.30 |
| Occupational function score: Week 12 (n=182, 171) | -1.49 ± 0.30 | -1.24 ± 0.30 |
| Cognitive function score: Week 3 (n=179, 169) | -1.33 ± 0.23 | -0.99 ± 0.23 |
| Cognitive function score: Week 6 (n=182, 171) | -2.12 ± 0.26 | -1.46 ± 0.26 |
| Cognitive function score: Week 9 (n=182, 171) | -2.30 ± 0.26 | -1.68 ± 0.27 |
| Cognitive function score: Week 12 (n=182, 171) | -2.59 ± 0.27 | -1.91 ± 0.28 |
| IP relationships score: Week 3 (n=179,169) | -1.57 ± 0.25 | -1.33 ± 0.26 |
| IP relationships score: Week 6 (n=182, 171) | -2.20 ± 0.28 | -1.91 ± 0.29 |
| IP relationships score: Week 9 (n=182, 171) | -2.41 ± 0.31 | -2.14 ± 0.31 |
| IP relationships score: Week 12 (n=182, 171) | -2.57 ± 0.31 | -2.31 ± 0.31 |
| Leisure time score: Week 3 (n=179, 169) | -0.50 ± 0.11 | -0.28 ± 0.11 |
| Leisure time score: Week 6 (n=182, 171) | -0.53 ± 0.13 | -0.34 ± 0.13 |
| Leisure time score: Week 9 (n=182, 171) | -0.52 ± 0.13 | -0.52 ± 0.13 |
| Leisure time score: Week 12 (n=182, 171) | -0.68 ± 0.13 | -0.59 ± 0.13 |
| Financial issues score: Week 3 (n=179, 169) | -0.78 ± 0.12 | -0.48 ± 0.12 |
| Financial issues score: Week 6 (n=182, 171) | -1.16 ± 0.12 | -0.76 ± 0.13 |
| Financial issues score: Week 9 (n=182, 171) | -1.25 ± 0.13 | -0.99 ± 0.13 |
| Financial issues score: Week 12 (n=182, 171) | -1.30 ± 0.12 | -1.07 ± 0.13 |
Response on the YMRS is defined as a 50% or greater improvement from baseline in YMRS total score. The YMRS is clinician-administered and consists of 11 multiple choice items. It is used to assess a patient's manic symptoms and clinical condition over the previous 48 hours. Total scores range from 0 to 60, with 12 or greater signifying hypomania or mania. Each item is given a severity rating ranging from 0 to 8 or 0 to 4. Items for the scale are based on the core symptoms of mania: elevated mood, increased motor activity, sexual interest, sleep, irritability, speech (rate and amount), language-thought disorder, content, disruptive-aggressive behavior, appearance, and insight. Scores for each item reflect the severity of that symptom in the patient. The test is administered during a clinical interview typically lasting 15-30 minutes. OC=observed cases.
| Percentage of participants | Placebo + Valproate or Lithium | Aripiprazole + Valproate or Lithium |
|---|---|---|
| Week 3 (n=183, 174) | 26.2 | 29.3 |
| Week 6 (n=186, 176) | 46.2 | 49.4 |
| Week 9 (n=186, 176) | 53.8 | 64.2 |
| Week 12 (n=186, 176) | 61.3 | 68.8 |
Remission is defined as a YMRS total score of 12 or less. The YMRS is clinician-administered and consists of 11 multiple choice items. It is used to assess a patient's manic symptoms and clinical condition over the previous 48 hours. Total scores range from 0 to 60, with 12 or greater signifying hypomania or mania. Each item is given a severity rating ranging from 0 to 8 or 0 to 4. Items for the scale are based on the core symptoms of mania: elevated mood, increased motor activity, sexual interest, sleep, irritability, speech (rate and amount), language-thought disorder, disruptive-aggressive behavior, appearance, and insight. Scores for each item reflect the severity of that symptom in the patient. The test is administered during a clinical interview typically lasting 15-30 minutes. LOCF=last observation carried forward.
| Percentage of participants | Placebo + Valproate or Lithium | Aripiprazole + Valproate or Lithium |
|---|---|---|
| Week 3 (n=183, 174) | 30.6 | 31.0 |
| Week 6 (n=186, 176) | 48.9 | 51.7 |
| Week 9 (n=186, 176) | 57.0 | 65.9 |
| Week 12 (n=186, 176) | 64.0 | 69.9 |
Adjusted mean change. The LIFE-RIFT total score ranges from 4 to 20 and is the sum of scores of 4 items: work, interpersonal relations, satisfaction, and recreation. A negative change score signifies improvement. OC=observed cases; LOCF=last observation carried forward.
| Units on a scale | Placebo + Valproate or Lithium | Aripiprazole + Valproate or Lithium |
|---|---|---|
| Week 6 (n=146, 135) | -2.13 ± 0.22 | -1.45 ± 0.23 |
| Week 12 (n=123, 115) | -3.20 ± 0.28 | -2.37 ± 0.28 |
| Week 12 (LOCF) (n=165, 150) | -2.30 ± 0.27 | -1.69 ± 0.28 |
Adjusted Mean Scores. The PGI-I is a self-administered 7-point scale, with scores ranging from 1 (very much improved) to 7 (very much worse), that assesses the improvement or worsening of a patient's illness relative to baseline at the beginning of the intervention. Scores: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; or 7=very much worse. OC=observed cases.
| Units on a scale | Placebo + Valproate or Lithium | Aripiprazole + Valproate or Lithium |
|---|---|---|
| Week 3 (n=178, 168) | 2.94 ± 0.10 | 2.99 ± 0.10 |
| Week 6 (n=151, 140) | 2.39 ± 0.11 | 2.64 ± 0.11 |
| Week 12 (n=127, 119) | 2.02 ± 0.12 | 2.24 ± 0.12 |
| Week 12 (LOCF) (n=181, 173) | 2.60 ± 0.13 | 2.88 ± 0.13 |
Adjusted mean change.OC=observed cases; LOCF=last observation carried forward.
| Kilograms | Placebo + Valproate or Lithium | Aripiprazole + Valproate or Lithium |
|---|---|---|
| Week 3 (n=177, 171) | -0.06 ± 0.16 | 0.14 ± 0.15 |
| Week 6 (n=152,144) | -0.02 ± 0.20 | 0.29 ± 0.21 |
| Week 9 (n=142, 128) | 0.07 ± 0.26 | -0.01 ± 0.26 |
| Week 12 (n=133, 123) | 0.22 ± 0.29 | 0.02 ± 0.29 |
| Week 12 (LOCF) (n=183, 174) | 0.11 ± 0.24 | 0.11 ± 0.23 |
Relevant weight gain=7% or greater increase in weight; relevant weight loss=7% or greater decrease in weight. LOCF=last observation carried forward.
| Percentage of participants | Placebo + Valproate or Lithium | Aripiprazole + Valproate or Lithium |
|---|---|---|
| Weight gain: Week 12 (n=184,174) | 4.3 | 5.2 |
| Weight loss: Week 12 (n=184,174) | 2.7 | 4.0 |
BMI=Weight in kilograms /(Height in meters\^2). LOCF=last observation carried forward.
| kg/m^2 | Placebo + Valproate or Lithium | Aripiprazole + Valproate or Lithium |
|---|---|---|
| Change From Baseline to Week 12 in Body Mass Index (BMI) (LOCF Data Set) | 0.0 (0.0 to 0.3) | 0.0 (0.0 to 0.4) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aripiprazole | — | 11/180 (6.1%) | 45/180 (25%) |
| Placebo | — | 17/189 (9%) | 29/189 (15.3%) |
| Event | Aripiprazole | Placebo |
|---|---|---|
| ManiaPsychiatric disorders | 2/180 | 7/189 |
| DepressionPsychiatric disorders | 4/180 | 2/189 |
| Alcohol abusePsychiatric disorders | 0/180 | 2/189 |
| HyperthermiaGeneral disorders | 1/180 | 0/189 |
| ComaNervous system disorders | 1/180 | 0/189 |
| Psychotic disorderPsychiatric disorders | 1/180 | 0/189 |
| Vertebrobasilar insufficiencyNervous system disorders | 1/180 | 0/189 |
| Bipolar I disorderPsychiatric disorders | 1/180 | 0/189 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 1/180 | 0/189 |
| Depression suicidalPsychiatric disorders | 1/180 | 0/189 |
| Event | Aripiprazole | Placebo |
|---|---|---|
| AkathisiaNervous system disorders | 20/180 | 4/189 |
| DepressionPsychiatric disorders | 14/180 | 5/189 |
| InsomniaPsychiatric disorders | 10/180 | 10/189 |
| NauseaGastrointestinal disorders | 10/180 | 5/189 |
| HeadacheNervous system disorders | 5/180 | 10/189 |
| Age Continuous(Years) | Placebo + Valproate or Lithium | Aripiprazole + Valproate or Lithium | Total |
|---|---|---|---|
| Mean | 44.92 ± 12.99 | 44.37 ± 12.13 | 44.65 ± 12.57 |
| Sex: Female, Male(Participants) | Placebo + Valproate or Lithium | Aripiprazole + Valproate or Lithium | Total |
|---|---|---|---|
| Female | 99 | 101 | 200 |
| Male | 90 | 80 | 170 |
| Race/Ethnicity, Customized(Participants) | Placebo + Valproate or Lithium | Aripiprazole + Valproate or Lithium | Total |
|---|---|---|---|
| White | 179 | 172 | 351 |
| Black/African American | 6 | 6 | 12 |
| Asian | 1 | 2 | 3 |
| Other | 3 | 1 | 4 |
The record gives a start of Jun 2008, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2013, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aripiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →